Chemosensitization by lipophilic nitroimidazoles

Area of Science:

• Radiobiology
• Experimental Therapeutics
• Cancer Research

Background:

• Lipophilic nitroimidazoles are investigated as radiosensitizers and chemosensitizers.
• Understanding drug interactions is crucial for optimizing cancer therapy.
• Previous studies explored misonidazole, prompting research into other nitroimidazoles.

Purpose of the Study:

• To evaluate the combined effects of lipophilic nitroimidazoles (Ro 07-1902 and benznidazole) with CCNU, cyclophosphamide, and melphalan.
• To determine the response of tumors (KHT sarcoma, RIF-1 sarcoma) and normal tissues in C3H mice.
• To assess potential therapeutic gains and toxicities associated with these drug combinations.

Main Methods:

• Experiments were conducted on C3H mice bearing KHT or RIF-1 tumors.
• Mice received combinations of lipophilic nitroimidazoles (Ro 07-1902, benznidazole) with CCNU, cyclophosphamide, or melphalan.
• Tumor response, white blood cell count depression, and median lethal dose (LD50/30) were assessed to calculate dose modifying factors (DMF).

Main Results:

• Maximum enhancement of KHT sarcoma response to CCNU was observed at low CCNU doses with Ro 07-1902 (DMF 2.5-3.0) and benznidazole (DMF 1.5-2.0).
• Therapeutic gain for CCNU was comparable to misonidazole, with lower toxicity to white blood cells and normal tissues.
• Significant tumor response enhancement (DMF 2.0) was noted with melphalan and both nitroimidazoles, though white blood cell depression was not greatly enhanced.

Conclusions:

• Lipophilic nitroimidazoles, particularly benznidazole, demonstrate therapeutic gain when combined with low-dose CCNU, offering a potential clinical advantage.
• The combination of benznidazole with melphalan shows promise for tumor response enhancement, but requires further investigation regarding toxicity.
• Cyclophosphamide response was not significantly enhanced by these lipophilic sensitizers at the tested doses.